drugset / Trial / NCT07712523
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.
Timeline
- Start
- 2025-11-05
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QY201 | Unknown | 5 mg | — |
| Subject | QY201 | Unknown | 10 mg | — |
| Subject | QY201 | Unknown | 20 mg | — |
Indications
No indication recorded.